Actinium Pharmaceuticals
ATNM
43 hedge funds and large institutions have $17.1M invested in Actinium Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 5 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
25% more capital invested
Capital invested by funds: $13.7M → $17.1M (+$3.47M)
16% more funds holding
Funds holding: 37 → 43 (+6)
1.02% more ownership
Funds ownership: 8.56% → 9.57% (+1%)
7% more call options, than puts
Call options by funds: $4.62M | Put options by funds: $4.32M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$327K |
| 2 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
+$261K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$215K |
| 4 |
D.E. Shaw & Co
New York
|
+$196K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$184K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$406K |
| 2 |
PA
Pinnacle Associates
New York
|
-$272K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$153K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$139K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$25.1K |
ATNM Hedge Fund Activity: Q3 2021 in Review
43 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2021, worth a combined $17.1M — up 25% from $13.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ATNM positions and 5 closed out — a net gain of 7 holders — while 13 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $327K. The largest seller was First Trust Advisors, exiting entirely with an estimated $406K sold.
- 43 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2021, up from 37 in Q2 2021.
- Funds reported $17.1M of Actinium Pharmaceuticals stock for Q3 2021, up 25% quarter-over-quarter.
- 12 funds opened new Actinium Pharmaceuticals positions in Q3 2021 and 5 closed out, a net change of +7 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2021 was Vanguard Group, an estimated $327K added.
- The largest Actinium Pharmaceuticals seller in Q3 2021 was First Trust Advisors, an estimated $406K sold.
Based on aggregated 13F filings for Q3 2021.